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Abstract
Background: A growing body of evidence indicates that inflammation is one of the earliest neuropathological
events in Alzheimer’s disease. Accordingly, we have recently shown the occurrence of an early, pro-inflammatory
reaction in the hippocampus of young, three-month-old transgenic McGill-Thy1-APP mice in the absence of
amyloid plaques but associated with intracellular accumulation of amyloid beta petide oligomers. The role of such
a pro-inflammatory process in the progression of the pathology remained to be elucidated.
Methods and results: To clarify this we administered minocycline, a tetracyclic derivative with anti-inflammatory
and neuroprotective properties, to young, pre-plaque McGill-Thy1-APP mice for one month. The treatment ended
at the age of three months, when the mice were still devoid of plaques. Minocycline treatment corrected the up-
regulation of inducible nitric oxide synthase and cyclooxygenase-2 observed in young transgenic placebo mice.
Furthermore, the down-regulation of inflammatory markers correlated with a reduction in amyloid precursor
protein levels and amyloid precursor protein-related products. Beta-site amyloid precursor protein cleaving enzyme
1 activity and levels were found to be up-regulated in transgenic placebo mice, while minocycline treatment
restored these levels to normality. The anti-inflammatory and beta-secretase 1 effects could be partly explained by
the inhibition of the nuclear factor kappa B pathway.
Conclusions: Our study suggests that the pharmacological modulation of neuroinflammation might represent a
promising approach for preventing or delaying the development of Alzheimer’s disease neuropathology at its
initial, pre-clinical stages. The results open new vistas to the interplay between inflammation and amyloid
pathology.
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Background
Alzheimer’s disease (AD) is a devastating neurodegenera-
tive condition affecting more than 35 million people
worldwide [1]. Neuropathological examination of the
brains of AD patients reveals intraneuronal neurofibrillary
tangles (composed of paired filaments of abnormally phos-
phorylated tau protein [2]), and massive accumulation of
extracellular amyloid plaques composed of aggregated
amyloid beta peptide (Ab) [3].
The initiating event for Ab production is the cleavage
of the amyloid precursor protein (APP) by the b site APP
cleaving enzyme 1 (BACE-1), a neuronal specific aspartyl
protease [4]. This event generates a soluble N-terminus
exodomain (soluble APPb) liberated into the lumen and
a b-C-terminus fragment (b-CTF) bound to the mem-
brane. Gamma secretase cleavage of the membrane-
anchored b-CTF releases Ab peptides of different
lengths, including Ab38, Ab40 and Ab42 [5]. Ab42 read-
ily aggregates into neurotoxic oligomers and eventually
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forms mature fibrils and plaques [6]. Amyloid plaques in
humans and animal models are invariably accompanied
by activated astrocytes and microglia with elevated levels
of pro-inflammatory products [7].
While Ab accumulation and aggregation are consid-
ered central events in the AD neuropathology, the
mechanisms that underlie these processes remain to be
elucidated. In particular, the role of neuroinflammation
in the progression of the disease is a matter of intense
debate. There is increasing awareness that the inflam-
matory response in neurodegeneration is a highly
dynamic process [8]. In AD, most studies have focused
on the late, plaque-associated glial activation; this phe-
nomenon has been the object of extensive investigations
and it has been well-characterized in the human brain,
in several animal models and in in vitro settings [7].
While fibrillar Ab-stimulated microglia are capable of
secreting toxic factors in vitro [9], peri-plaque microglia
appear to elicit mostly beneficial effects in vivo, limiting
plaque growth by phagocytosing Ab and releasing neu-
rotrophic factors [10,11]. In agreement with such obser-
vations, prospective clinical trials with anti-inflammatory
drugs in patients with AD have shown no effect, or even
a worsening of the pathology [12-14]. On the other
hand, epidemiological data demonstrated that life-long
users of nonsteroidal anti-inflammatory drugs (NSAIDs)
develop AD with reduced frequency. This association
suggests the existence of a latent pre-clinical inflamma-
tory process which would facilitate the disease progres-
sion (for a review, see [15]).
Besides the epidemiological studies, a growing body of
evidence in the literature supports the concept that
inflammation is an early event in the progression of AD.
Microglial activation could be detected in patients with
mild cognitive impairment (MCI), which represents the
prodromal stage of AD [16-19]. Furthermore, gliosis and
up-regulation of IL-1b have been reported in fetal and
neonate patients with Down syndrome [20]. Since indivi-
duals with Down syndrome invariably develop plaque
pathology by mid-age, prenatal and neonatal samples can
be considered as pre-plaque conditions.
Taken together, the available evidence strongly indi-
cates that microglial activation occurs early in the pro-
gression of the disease. It is very likely that the glial
response at the first stages of the neurodegenerative pro-
cess differs significantly from the well-established peri-
plaque inflammation, and could accelerate the onset of
the disease. Unfortunately, direct investigation of micro-
glial activation and its role in pre-clinical stages of AD is
complicated by the fact that it is impossible to predict
the conversion of individuals with no cognitive impair-
ment into individuals with MCI or AD. Therefore, very
little is known about the status of microglial activation
and its role in the earliest, pre-clinical stages of AD.
In this regard, transgenic (Tg) animal models, which
faithfully recapitulate the main hallmarks of the AD-like
amyloid pathology, offer the opportunity to investigate
events associated with the progression of the disease. It is
becoming increasingly clear that Tg mice with extensive
plaque deposition but without neurofibrillary tangles and
neuronal loss represent a relatively early stage of the
pathology compared to a human brain and are most likely
models of early AD and MCI [21]. Accordingly, pre-plaque
APP-Tg mice can be valuable tools to elucidate even ear-
lier events preceding plaque deposition.
Using this approach, we have recently described the
occurrence of an early, pre-plaque inflammatory response
in our newly generated McGill-Thy1-APP mouse Tg
model of AD-like amyloid pathology that would mimic
the pre-morbid AD. In this Tg model, plaque deposition
begins around four to five months of age [22]; however,
up-regulation of inflammatory markers and activation
and mobilization of microglia can be detected as early as
three months of age [23]. Indications of pre-plaque
inflammation have also been reported for other models
such as APP(V717) [24], R1.40 [25] and 3xTg [26]. How-
ever, the role of such early neuroinflammation in the pro-
gression of the amyloid pathology had not yet been
determined.
To define the role of the early, pro-inflammatory events
observed at pre-plaque stages of the AD-like amyloid
pathology, we tested the therapeutic effect of minocycline,
a tetracyclic derivative with anti-inflammatory properties,
in young, pre-plaque McGill-Thy1-APP Tg mice. The
treatment lasted one month and ended when the mice
were three months old, thus prior to the appearance of the
first plaques. This strategy allowed us specifically to inves-
tigate the role of inflammation in early, pre-plaque stages
of the amyloid pathology, which should correspond to the
earliest, pre-clinical stages in the human. We gathered bio-
chemical and morphological evidence indicating that early,
pre-plaque neuroinflammation can be blocked by minocy-
cline treatment. The reduction of inflammatory markers
was accompanied by reduced activity of BACE-1 and cor-
rection of the nuclear factor-kappa-light chain enhancer of
activated B cells (NFkB) pathway.
Materials and methods
Animals and treatment
For these studies we used our in-house APP Tg mouse
model of AD-like amyloid pathology, coded McGill-Thy1-
APP [22]. The mice carry the human APP transgene with
the Swedish and the Indiana mutations under the control
of the murine Thy1.2 promoter. All the animals were two
months old when they started the treatment, and were
sacrificed at three months of age. Young, pre-plaque two-
month-old Tg mice received minocycline by intraperito-
neal injection for one month (Tg Mino, n = 7); control
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groups included vehicle-treated Tg mice (Tg Placebo, n =
7), vehicle-treated non Tg, age-matched littermates (Non
Tg Placebo, n = 8) and non Tg, age-matched littermates
treated with minocycline (Non Tg Mino, n = 8). All the
animals received intraperitoneal injections of 200 uL of
solution, alternating the injection side, every day for one
month. Minocycline hydrochloride was purchased from
Sigma-Aldrich Canada (M9511; Oakville, ON, Canada)
and a fresh solution of 5 mg/mL (10 mM) was prepared in
filtered PBS and stored at -80°C for one week. Since the
pH of minocycline hydrochloride is acidic (pH 4), we cor-
rected it to neutrality by adding sodium hydroxide (as
described by [27]). Minocycline-treated animals received a
dose of 50 mg/Kg/day (200 μL of 5 mg/mL solution equat-
ing to 1 mg, which, for an average mouse weighing 20 g,
corresponds to 50 mg/Kg). This dose is similar to previous
studies [28] and is expected to result in micromolar con-
centrations of the drug in the brain [29]. Placebo animals
received an equal volume of filtered PBS, pH 7.4.
The animals were housed in groups of up to four in
individually ventilated cages under standard conditions
(22°C, 12 h light-dark cycle) receiving food and water ad
libitum. All procedures were approved by the Animal
Care Committee of McGill University and followed the
guidelines of the Canadian Council on Animal Care. After
three weeks of the treatment, one Non Tg Mino mouse
had to be euthanized for a swollen intestine and two Tg
Mino mice died (no statistical difference was found in the
mortality across genotypes, P = 0.59, chi-squared test). No
mice died in the placebo groups. At the end of the treat-
ment the animals (Non Tg Placebo: n = 8, six females and
two males; Tg Placebo: n = 7, five females and two males;
Non Tg Mino: n = 7, six females and one male; Tg Mino:
n = 5, two females and three males) were sacrificed by
transcardial perfusion and the brains processed for bio-
chemical and immunohistochemical analysis.
Perfusion and tissue preparation technique
Tg and Non Tg littermate mice were deeply anesthetized
with equithesin (pentobarbital-based, 2.5 mL/Kg, intraper-
itoneal injection) and perfused through the heart with ice-
cold saline solution (pH 7.4) for 1 minute. The brains
were then quickly removed and divided into right and left
hemisphere on ice. The cortex, hippocampus and cerebel-
lum were dissected from the left hemisphere, snap-frozen
in dry ice and stored at -80°C for biochemical analysis.
Cortical samples were used for the determination of
inflammatory marker levels and APP-related products,
while hippocampi were used for BACE-1 activity assay
and BACE, NFkB and inhibitor of kb (IkB) quantification.
The right hemisphere was fixed in 4% paraformaldehyde
in 0.1 M phosphate buffer (pH 7.4) for 24 hours at 4°C.
The tissue was then cut into 40-μm thick sections with a
freezing sledge microtome (SM 2000R, Leica, Wetzlar,
Germany) and free-floating sections were collected in PBS
and processed for immunohistochemistry.
Western blotting
Inflammatory markers
Cortical samples from the left hemisphere were homoge-
nized in 250 μL of lysis buffer (50 mmol/L Tris-HCl, 150
mmol/L sodium chloride, 1% Nonidet P-40, 0.1% sodium
dodecyl sulfate, 0.1% deoxycholic acid, 2 μg/mL of aproti-
nin, 2 μg/mL of leupeptin, 100 μg/mL phenylmethanesul-
fonyl fluoride, pH 7.4). The samples were centrifuged at
13,000 rpm for 45 minutes at 4°C. Following total protein
content quantification (Dc-protein assay, Bio-Rad, Her-
cules, CA, USA), 100 μg of protein were separated using
10% SDS-PAGE and semi-dry transferred to nitrocellulose
membranes for subsequent western blotting. Membranes
were blocked with 5% non-fat milk in Tris-buffered saline
(TBS) containing 0.1% Tween 20 (TBS-T) and then incu-
bated with the primary antibody overnight at 4°C. Primary
antibodies used were rabbit polyclonal anti-inducible nitric
oxide synthase (iNOS) and IL-1b (both 1:500; Santa Cruz
Biotechnology Inc., CA, USA); cyclooxygenase-2 (COX-2;
1:2000; Cayman Chemicals, Ann Arbor, MI, USA); and
mouse monoclonal anti bIII-tubulin (1:40,000; Promega,
Madison, WI, USA). Horseradish peroxidase (HRP)-conju-
gated anti-rabbit and anti-mouse secondary antibodies
were purchased from Jackson (Jackson Immunoresearch
Laboratories, West Grove, PA, USA). The HRP signal was
revealed with a chemiluminescence assay (ECL, GE
Healthcare, Amersham, UK) on films. Signal intensity was
quantified by densitometry (MCID4 image analysis system,
Imaging Research Inc., St. Catherine’s, ON, Canada). The
levels for each marker were normalized with respect to
bIII-tubulin (neuronal specific) immunoreactivity. All
experiments were performed in triplicate.
Tris-tricine western blotting for amyloid precursor protein
and amyloid precursor protein-related products
Total proteins (100 to 250 μg) from the cortical homoge-
nates (prepared as indicated above) were run in pre-cast
commercially available 10 to 20% Tris-tricine gels (Criter-
ion, Bio-Rad Laboratories). The proteins were semi-dry
transferred on nitrocellulose (for 6E10 detection) or poly-
vinylidene fluoride (for pab27576) for 2 hours at 12 V.
The membranes were boiled for 5 minutes in PBS, then
blocked for 2 hours with milk 10% and incubated with the
specific antibody over night at 4°C. Antibodies used were
monoclonal mouse antibodies 6E10 (1:1000; directed
against the residues 1 to 16 of human Ab; from Signet,
provided by Covance, Princeton, NJ, USA) and neuron
specific bIII tubulin (1:40,000; Promega); and rabbit poly-
clonal pab27576 (1:250; directed against the C-terminus of
APP; a generous gift from Dr Multhaup, Freie University,
Berlin). The quantification was performed as described
above; for CTF, the duplet was quantified. For the
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calibration curve, a recombinant CTF (C100 protein puri-
fied recombinantly from Escherichia coli) was used (gener-
ous gift from Dr Multhaup). The C100 had a C-terminal
hexa-His tag and an N-terminal start-methionine. The
calibration curve appeared to be linear (r2 = 0.99) in the
range between 7 and 0.43 ng per lane.
b-site APP cleaving enzyme 1, nuclear factor kappaB and
inhibitor of kb
The hippocampi were briefly sonicated in 100 μL of Cell
Extraction Buffer (provided with the BACE activity kit, see
below), incubated on ice for 15 minutes and centrifuged at
10,000 rpm for 5 minutes at 4°C. The protein content was
quantified as described above and 100 μg of total protein
was separated using 10% SDS-PAGE and transferred to
polyvinylidene fluoride membrane for subsequent western
blotting. Membranes were blocked with 5% non-fat milk
in TBS-T and then incubated with the primary antibody
overnight at 4°C. The primary antibodies used were rabbit
polyclonal BACE-1 (PA1-757, 1:250; Thermo Scientific
Pierce antibodies, Meridian Road Rockford, IL, USA);
NFkB (p65, 1:1000) and IkB (1:2000; both from Santa
Cruz Biotechnology Inc.); and actin (1:20,000; Abcam,
Cambridge, MA, USA). Band quantification was per-
formed as described above. All experiments were per-
formed in triplicate.
Immunohistochemistry and quantification of ionized
calcium-binding adaptor molecule 1 immunoreactive cells
Bright field immunohistochemistry
Free-floating immunohistochemical staining was per-
formed as previously described [30,31] using the rabbit
polyclonal primary antibody ionized calcium-binding
adaptor molecule 1 (Iba-1; 1:10,000; Wako Chemicals
USA, Inc., Richmond, VA, USA). For the detection, a bio-
tinylated goat anti-rabbit secondary antibody was applied
followed by amplification with the avidin-biotin complex
(ABC elite kit, both from Vector Laboratories Inc., Burlin-
game, California, USA). All stainings were developed with
0.06% 3,3’-diaminobenzidine (Sigma-Aldrich Canada) and
0.01% hydrogen peroxide.
Quantification of ionized calcium-binding adaptor molecule
1-immunoreactive cell soma size and density
The staining and the quantification of Iba-1 immunor-
eactive (ir) cells were performed according to published
protocols [23]. All the stainings were performed simulta-
neously. Three sections per animal were chosen in the
area corresponding to bregma -2.9 [32], stained with Iba-
1 and mounted on gelatinated slides, after which the
slides were coded. Digital images were acquired on an
Axioplan 2 Imaging microscope (Zeiss, Toronto, ON,
Canada), equipped with an AxioCam HRc digital camera
(Zeiss), using AxioVision 4 Imaging program (Zeiss). The
micrographs were taken with a 63× Zeiss plan-Apochro-
mat oil immersion objective in the CA1 area of the
hippocampus (eight micrographs per section, three sec-
tions per animal for a total of 24 micrographs per ani-
mal,) and, as a control, four micrographs were taken in
the lateral posterior thalamic nucleus (total of 12 micro-
graphs per animal). The images were imported into the
MCID 5 Image Analysis Software (Imaging Research
Inc.) as tagged image file format files and transformed
(with the ‘target accent’ function) to allow optimal detec-
tion by the program. Cell bodies of all the cells in the
focal plane of each micrograph were manually outlined
by a blinded observer before target size, number of target
elements, intensity and form factor were measured in an
automatic fashion. After quantification, the slides were
decoded and the data analyzed. The density data are
expressed as the number of Iba1-ir cells per field (38.206
μm2). MTF was blind to the nature of the material at all
stages of the quantification.
Enzyme-linked immunosorbent assay for human amyloid
beta peptide
Human Ab40 and Ab42 levels were quantified from corti-
cal homogenates using a commercially available ELISA kit
(Invitrogen, Carlsbad, CA, USA; distributed by Medicorp,
Montreal, Canada). Each sample was mixed in an equal
volume of guanidine-HCl (to a final concentration of 5 M
guanidine) and incubated for 3 hours at room tempera-
ture. The resulting samples were further diluted 1:10 in
the provided dilution buffer (to a final concentration of 0.5
M guanidine) and tested in duplicate. The amount of Ab
was extrapolated from a calibration curve of synthetic
human Ab40 and Ab42 using the curve fitting function of
Graph-Pad Prism 5 software (La Jolla, CA, USA). The cali-
bration curve was prepared according to the manufac-
turer’s instructions in the presence of 0.5 M guanidine to
ensure comparability with experimental samples. The data
were normalized on total micrograms of protein content
per sample. Controls included: omission of samples (back-
ground), chromogenic substrate alone (blank) and Non Tg
samples. No signal was detectable in Non Tg samples
(data not shown).
b-site APP cleaving enzyme 1 activity
We used two commercially available kits for the measure-
ment of BACE-1 enzymatic activity from the biological
samples (R&D, Minneapolis, MN, USA and Abcam, Cam-
bridge, MA, USA). The assay was conducted according to
manufacturer’s instructions. Briefly, hippocampal samples
(see above for preparation details) were diluted to a final
concentration of 2.5 μg/50 μL. From the resultant samples,
2.5 μg of total protein were loaded into a black 96-well
microplate and the fluorogenic substrate was added in the
dark. The substrate is conjugated to the EDANS and
DABCYL reporter molecules. Cleavage of the peptide by
b-secretase separates EDANS and DABCYL, allowing for
the release of a fluorescent signal. The reaction was incu-
bated at 37°C for one hour in the dark, and the signal was
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measured using a Fluostar Optima (BMG Labtech GmbH,
Ortenberg, Germany) with 355 nm excitation and 520 nm
emission wavelengths. Each sample was run in duplicate;
the assay was repeated twice and results from the two
experiments were pooled after normalization on Non Tg
Placebo values. Negative controls included: omission of
the fluorogenic peptide (background fluorescence of the
tissue), omission of the sample (blank) and addition of
BACE-1 inhibitor to the samples (provided by the kit). We
ran 2.5 μg of recombinant human peptide (rhBACE-1:
R&D) as a positive control.
Postnatal day 7 samples for b-site APP cleaving enzyme
1 western blot
Two pups from postnatal day 7 were sacrificed and the
brains carefully removed; one brain was immediately
homogenized as described above for regular western
blotting, while the cortex of the second brain was used
to establish a mixed glial culture according to standard
protocols with minor modifications [33]. Briefly, the
cells were disaggregated using papain (Worthington,
Lakewood, NJ, USA) and mild mechanical stress with a
polished Pasteur pipette. The cells were then re-sus-
pended in DMEM containing 10% FBS and penicillin-
streptomycin, and cultured in a 10-cm petri dish. The
medium was changed every three to four days and after
two weeks the cells were collected by scraping on ice,
then sonicated and processed for western blotting.
Data analysis
All data were analyzed using the Graph-Pad Prism 5 soft-
ware (La Jolla). Multiple groups’ comparison was done by
one-way analysis of variance (ANOVA) followed by Tukey
post-hoc test. Kruskal-Wallis was used for non-normally
distributed data. The interaction between the genotype
and effect of the drug was studied using two-way
ANOVA. Correlation studies were done using the Spear-
man’s test for non-normally distributed data. Significance
was set at P < 0.05. All data are presented as mean ± stan-
dard error of the mean.
Results
Minocycline corrects neuroinflammation in pre-plaque
McGill-Thy1-APP Tg mice
We first assessed the ability of minocycline to reduce the
central nervous system (CNS) pro-inflammatory process
in young, pre-plaque Tg mice by measuring levels of
iNOS, COX-2 and IL-1b via western blotting (Figure 1A-
C). Confirming and further expanding our previous sets of
experiments [23], we found that iNOS and COX-2 were
significantly up-regulated in cortical homogenates from
Tg mice compared to Non Tg littermates (Figure 1A, B,
P < 0.05). IL-1b showed a trend towards up-regulation
which did not reach significance (Figure 1C). Minocycline
treatment was able to inhibit neuroinflammation, as the
levels of iNOS, IL-1b and COX-2 of Tg mice treated were
significantly different from Tg Placebo (P < 0.01) but not
significantly different from Non Tg controls.
Minocycline treatment did not significantly alter the
levels of these markers in Non Tg animals. The follow-
ing fold increases compared to Non Tg Placebo were
observed in Non Tg Mino: iNOS, 1.49 ± 0.19; IL-1b,
0.99 ± 0.04; COX-2, 1.31 ± 0.15. None of these reached
significance (P = 0.08, 0.95 and 0.31, respectively; Stu-
dent’s t-test), even though a trend was observed for the
iNOS levels.
To confirm the biochemical data, we used a morpholo-
gical approach to study the activation state of microglial
cells. Iba-1, a structural marker for microglia [34], was
used to stain brain sections from Tg and Non Tg animals.
As expected, most microglial cells in Non Tg Placebo
mice displayed a resting morphology, with a small soma
size and symmetrical, fine arborization of the processes
(Figure 1E). As previously reported, we observed an
altered morphology of the microglial cells from the hippo-
campus of Tg Placebo animals. The cells displayed an
enlarged soma size, with notable polarization and thicken-
ing of the processes, all indicative of microglial activation.
In contrast, microglial cells from minocycline-treated Tg
animals (Tg Mino) displayed a small, roundish soma, simi-
lar to Non Tg Placebo. Interestingly, we noticed an
increase in the complexity of microglia ramification fol-
lowing minocycline treatment in Tg animals; the number
of processes emanating from the cells appeared to be ele-
vated and they were often thick and decorated by spines.
Microglial soma size and density was measured with the
assistance of the MCID 5 Image Analysis System, accord-
ing to published protocols [23]. Reinforcing our biochem-
ical results, we observed a significant down-regulation of
microglial cells size in the hippocampus of Tg animals
treated with minocycline (Figure 1G, P < 0.05) indicative
of a reduced activation or reversal to a resting state. No
differences in the density of microglial cells were observed,
suggesting that the effect of minocycline was not mediated
by a reduction in microglial proliferation.
No significant differences were found between the
microglial soma size in Non Tg Placebo (38.86 μm2 ±
0.37) and Non Tg Mino (39.64 μm2 ± 1.16).
The analysis of microglial morphology was performed in
the lateral posterior thalamic nucleus in the same sections
(Figure 1F) as a control area which is spared by the amy-
loid pathology at this age [22]. In agreement with previous
reports [35], we noticed that microglial cells in this area
were smaller, less ramified and less dense than in the hip-
pocampus. The analysis of microglial cells soma size and
density in the thalamus revealed no differences between
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Figure 1 Minocycline corrects neuroinflammation in young, pre-plaque Tg mice. (A-C) Representative western blots for iNOS, COX-2 and
IL-1b (typical markers of microglial and neuronal activation) in control, Non Tg Placebo mice (Non Tg), Tg Placebo mice (Tg Pl) and Tg mice
treated with minocycline (Tg Mino). Note the significant up-regulation of iNOS and COX-2 in Tg Pl compared to Non Tg. Minocycline restored
iNOS and COX-2 to levels similar to those of Non Tg, and significantly reduced the levels of IL-1b (* P < 0.05, **P < 0.01, one-way ANOVA with
Tukey post-hoc test). See main text for the values of Non Tg treated with minocycline. (D) Schematic illustrating the sampling of images in the
CA1 area of the hippocampus and from the lateral posterior thalamic nucleus as utilized for the morphological study represented in E-G. (E)
Representative micrographs illustrating the ir of Iba-1 in microglial cells in the hippocampus of the Non Tg, Tg Pl and Tg Mino mice. Note the
altered morphology of the microglial cells in Tg Pl compared to Non Tg. In Tg Pl mice, we observed an enlargement of the soma size,
polarization and thickening of the microglial processes, which are classical indicators of microglial activation. Minocycline treatment resulted in
correction of microglial soma size (note the small, roundish morphology), with some residual thickening of processes and increase in spiny
processes. (F) Representative micrographs illustrating the ir of Iba-1 in microglial cells in the lateral posterior thalamic nucleus of the Non Tg, Tg
Pl and Tg Mino. The cells were notably smaller and less ramified than in the hippocampus, but no differences in the morphology could be
observed between experimental groups. Scale bar for E and F: 20 μm. (G,H) Quantification of cell soma size and density of microglial cells from
hippocampus (G) and thalamus (H) in Non Tg, Tg Pl and Tg Mino. Note that minocycline treatment resulted in significant reduction of microglial
cells soma size compared to Tg Pl in the hippocampus (G). No significant differences were observed in the soma size of cells in the thalamus
(H). As previously reported [23], no significant changes in microglial cell density were observed between Non Tg and Tg. This pattern was not
altered across experimental groups in any area. (* P < 0.05, one-way ANOVA followed by Tukey post-hoc test). Non Tg: Non Tg Placebo mice; Tg
Mino: Tg mice treated with minocycline; Tg Pl: Tg Placebo.
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groups (Figure 1H). This result indicated that the effect of
minocycline was specific to the hippocampus, an area bur-
dened with intracellular Ab-ir material.
Minocycline treatment affects amyloid precursor protein
metabolism
Next, we investigated the effects of the anti-inflammatory
treatment on APP metabolism and Ab levels (Figure 2).
For these studies we used cortical homogenates from Tg
Placebo and Tg Mino.
We first applied the commercially available monoclonal
antibody 6E10, which recognizes residues 1 to 16 of
human Ab. This western blot analysis revealed several ir
bands in Tg Placebo animals between 10 kDa and 50 kDa.
These bands did not appear in the Non Tg homogenates,
and are likely to be oligomeric forms of Ab. Minocycline
treatment resulted in the clearance of most of the 6E10-ir
bands; in particular, a strong (-70%), significant down-reg-
ulation of a 12-kDa band (Figure 2A and 2B) was
observed. We noticed that the levels of the 12-kDa band
strongly correlated with the levels of iNOS across samples
(Figure 2C, r= 0.81, P = 0.004, Spearman’s correlation ana-
lysis). In these experimental cohorts, Tg Placebo mice dis-
played the highest values for both 12 kDa-6E10 and iNOS,
while all but one of the Tg mice treated with minocycline
displayed reduced levels of both markers. These results
would suggest a link between APP metabolism and the
inflammation staging.
The 12-kDa band could not be definitively identified. In
fact, the 6E10 antibody is directed against the N-terminus
residues of Ab and therefore can recognize both b-CTF
fragments of APP (that migrate around 12 kDa) and Ab
species (such as Ab-trimers). To elucidate the nature of
the 12-kDa band, we performed additional analysis on the
homogenates that enabled us to specifically quantify the
amount of CTF fragments and human Ab.
To detect CTF fragments without cross-reactivity with
Ab, we used a specific antibody directed against the C-ter-
minus of the APP holoprotein pab27576 (generous gift
from Dr Multhaup, Freie University, Berlin [36]). This
serum recognizes full-length APP (flAPP, which appeared
at 100 kDa) and CTFs (which migrated around 12 kDa).
In order to quantify the levels of CTF in the sample, in the
same gels we included a calibration curve of recombinant
CTF (Figure 2D). After this analysis, we quantified the
levels of flAPP and CTF fragments (Figure 2E). We
observed a significant down-regulation of flAPP relative
levels (Figure 2E, P < 0.01) in Tg Mino animals compared
to Tg Placebo. The down-regulation of flAPP was con-
firmed using other APP-specific antibodies such as 6E10
and 22 C11 (data not shown).
Extrapolation of the levels of CTF in the brain homoge-
nates from the calibration curve revealed that Tg Placebo
animals had 10.13 ± 3.50 ng of CTF per milligram of total
protein. In the Tg Mino group, CTF fragments (both rela-
tive and absolute levels) appeared reduced (7.27 ± 1.34 ng/
mg) but such reduction did not reach significance. Impor-
tantly, the decrease in CTF following minocycline treat-
ment was not completely explained by the reduction in
APP levels. In fact, when we normalized the CTF levels on
flAPP levels, the trend towards a reduction was still pre-
sent (Figure 2E, ratio CTF/flAPP). These results suggested
that the 12-kDa band recognized by 6E10 was not exclu-
sively constituted by CTF, as the values detected by the
two antibodies were not perfectly correspondent. We
therefore sought to quantify Ab levels in the same
samples.
To obtain a direct quantitative measurement of the
Ab levels we performed an ELISA analysis of human
Ab40 and Ab42. The study revealed the presence of
160.9 ± 24.37 pg/mg total protein of Ab42 and 38.28 ±
4.25 pg/mg total protein of Ab40 in Tg Placebo animals.
After minocycline treatment we measured 109.0 ± 13.43
pg/mg total protein of Ab42 and 28.76 ± 2.42 pg/mg of
Ab40. Though a strong trend was observed towards
reduction (P = 0.08 and 0.09, respectively), this did not
reach significance (Figure 2F).
We then calculated the ratio between Ab (pg/mg total
protein) and CTF (ng/mg total protein) in each sample:
this analysis revealed that in the Tg Placebo animals there
were 24.29 ± 6.43 pg of Ab42 and 6.76 ± 2.15 pg of Ab40
per each nanogram of CTF. A trend towards a decrease in
animals treated with minocycline was found (15.14 ± 3.08
pg of Ab42 and 4.36 ± 0.58 pg of Ab40 per each nano-
gram of CTF), suggesting fewer molecules of Ab per mole-
cule of CTF following minocycline treatment (Figure 2G).
Minocycline inhibits b-site APP cleaving enzyme 1 activity
in young, pre-plaque Tg mice
The strong reduction of the 12-kDa band immunoreactive
with 6E10 and the altered CTF/flAPP ratio observed after
minocycline treatment would indicate that the b cleavage
of APP could be affected by the anti-inflammatory drug.
Therefore, we proceeded to measure BACE-1 activity in
the hippocampal samples, using a well-characterized
fluorometric assay (Figure 3A and 3B). This kit allowed
specific and robust detection of BACE-1 from brain
homogenates; the fluorescent signal detected in brain
homogenates was seven times higher that background,
and was reduced to background levels by co-incubation
with the kit BACE inhibitor (Figure 3B).
With this approach we found that Tg animals displayed
significantly increased BACE-1 activity compared to Non
Tg (P < 0.001). Supporting our biochemical findings on
APP processing, we found that minocycline was able to
reduce BACE-1 activity in Tg animals, and blunted it to
levels that were similar to Non Tg (P < 0.05 Tg placebo
versus Tg Mino). On the other hand, Non Tg animals
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receiving minocycline also displayed up-regulation of
BACE-1 activity. A two-way ANOVA revealed that there
was a strong interaction between the genotype and the
treatment (P < 0.001), suggesting that minocycline
exerted differential effects according to the genotype.
We used western blotting to quantify BACE-1 levels in
the same samples to assess whether the effect observed
was due to a pure enzymatic inhibition or to reduction
in the protein content (Figure 3D). Even though this
assay appeared to be less sensitive than the enzymatic
Figure 2 Minocycline effects on amyloid precursor protein metabolism. Cortical brain homogenates from Tg animals treated with vehicle
(Tg Pl) or minocycline (Tg Mino) were subjected to western blotting and ELISA to determine the levels of Ab species, full-length APP (flAPP) and
CTF. (A) Representative western blot of cortical homogenates from Tg animals treated with vehicle or with minocycline, using 6E10 antibody.
Note the strong down-regulation of the approximately 12-kDa ir band (indicated with an asterisk) which likely represents a mixture of b-CTF of
APP and Ab trimers. (B) Densitometric analysis of the 12-kDa band detected with 6E10. Values were normalized on neuronal specific b-tubulin.
Minocycline-treated animals showed significantly lower levels compared with placebo (**P < 0.01, Student’s t-test). (C) Correlation analysis of the
levels of the 12-kDa band ir to 6E10 and the levels of iNOS per sample. The correlation was found to be highly significant (r = 0.81; P = 0.004,
Spearman’s correlation), where Tg Placebo animals (black dots) had the highest levels of 6E10-ir and iNOS, while Tg Mino (yellow dots) mice
displayed reduced levels of ir with 6E10 and lower levels of iNOS. (D) Representative western blots of cortical (ctx) homogenates from placebo
and minocycline-treated animals using the pab27576 antibody. This antibody recognizes an epitope on the C-terminus of APP and therefore
detects two prominent bands in the blots: a high molecular weight band (about 100 kDa), corresponding to flAPP and a faster band
(approximately 12 kDa) corresponded to the CTF fragments. A calibration curve using known amounts of recombinant C100 was run in the
same gel for quantification purposes (the recombinant peptide ran slightly slower due to the presence of a C-terminal hexa-His tag). (E)
Quantification of flAPP and CTF levels in cortical homogenates from Tg Placebo and Tg-treated animals. FlAPP relative optical density values
were normalized on neuronal specific b-tubulin. Note the significant down-regulation of flAPP (**P < 0.01, Student’s t-test) in Tg Mino compared
with Tg Placebo. CTF absolute levels were extrapolated from the calibration curve of recombinant CTF. There was a non-significant trend
towards reduction following minocycline treatment. Normalization of the relative optical density of CTF over the relative optical density of flAPP
confirmed a non-significant trend towards a reduction (ratio CTF/flAPP). All data were analyzed with Student’s t-test. (F) Quantification of human
Ab levels in cortical homogenates from Tg Placebo and Tg Mino using ELISA. The treatment reduced both Ab40 and Ab42, but the effect did
not reach significance (P = 0.09 and 0.08, respectively, Student’s t-test; see main text for exact values). (G) The ratios between Ab (pg/mg total
protein) and CTF (ng/mg total protein) were calculated per sample and compared across groups. We observed 24.29 ± 6.43 pg of Ab42 and
15.14 ± 3.08 pg of Ab40 per each nanogram of CTF. Minocycline treatment resulted in a reduction of the ratio (which did not reach
significance), suggesting that less Ab was produced per CTF molecule after the treatment with minocycline.
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activity assay, we found a significant up-regulation of
BACE-1 protein levels in Tg animals compared to Non
Tg (Figure 3E, P < 0.05). Minocycline-treated animals
had intermediate levels of BACE-1, which were not sig-
nificantly different from the Tg Placebo nor from the
Non Tg levels. Confirming our activity data, Non Tg
treated with minocycline displayed elevated levels of
BACE-1 (interaction between genotype and treatment: P
< 0.01, two-way ANOVA). The band observed was most
likely specific, as it did not appear in naive glial cultures
from mice pups and was barely detectable in cerebellum
(Figure 3C).
Taken together, these results demonstrated that Tg
animals, even prior to plaque deposition, showed
increased levels and activity of BACE-1. Such up-regula-
tion is likely to be related to an inflammatory process,
as minocycline could significantly reduce BACE-1 activ-
ity and corrected BACE-1 levels.
BACE-1 and many inflammatory mediators such as
iNOS, COX-2 and IL-1b are known to be under the
transcriptional control of NFkB [37,38]. The active form
of human NFkB is a dimer composed of the two DNA
binding subunits p50 and p65. These genes are constitu-
tively expressed in both glia and neurons and their
Figure 3 Minocycline inhibits b-site APP cleaving enzyme 1 in young, pre-plaque Tg mice. (A) BACE-1 activity was quantified from
hippocampal homogenates using a well-characterized fluorometric assay. Fluorescent units (FU) data were normalized on Non Tg Placebo
values. Note the significant up-regulation of BACE-1 activity in Tg Placebo compared to Non Tg Placebo (***P < 0.001), which was corrected
following minocycline treatment (*P < 0.05 compared to Tg Placebo). (B) Specificity of the BACE-1 fluorometric assay: note how the fluorescent
units detected from brain homogenates (of a Non Tg Placebo animal) are seven times higher than the background (bg). The signal was
completely abolished by co-incubation with a specific BACE inhibitor (BACEi), and was in the range of activity of a recombinant human BACE
protein (rhBACE, 2.5 μg). All the data were analyzed with one-way ANOVA followed by Tukey post-hoc test. (C) Specificity of the polyclonal
BACE-1 antibody used for western blotting: the specific band (close to 75 kDa) appeared in brain extracts from post natal day 7 (pnd 7) and
from adult cortex (ctx), while it was hardly detectable in cerebellum (cereb) sample and was not detectable in a glial preparation from pups. (D)
Representative western blots of BACE-1, NFkB and IkB from the same hippocampal samples used for the enzymatic assay (ns = non-specific
band recognized by the polyclonal antibody directed against NFkB). (E) Quantification data of BACE-1, NFkB and IkB from hippocampal
homogenates. Band intensity was quantified via densitometry and the values were normalized on the neuronal specific-b-tubulin content. Note
the significant up-regulation of BACE-1 levels in Tg Placebo, which was corrected by the minocycline treatment (P < 0.05). The levels of NFkB
and BACE-1 in each sample strongly correlated (P < 0.001, Spearman’s correlation analysis). Given the not-normal distribution of the data, the
values were analyzed with Kruskal-Wallis test and Spearman’s correlation analysis. BACEi: BACE inhibitor; bg; background; cereb: cerebellum; ctx:
cortex; pnd: postnatal day; rhBACE: recombinant human BACE.
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mRNA levels are further increased in response to
inflammatory signals. Dimers are normally in an inactive
form, sequestered in the cytoplasm by the NFkB inhibi-
tor, IkB (for a review, see [38]). Activation by inflamma-
tory stimuli results in phosphorylation and degradation
of IkB, translocation of NFkB into the nucleus and
expression of target genes. Target genes include inflam-
matory cytokines, chemokines, acute phase proteins and
immune receptors [37]; interestingly, IkB gene also con-
tains NFkB binding sites [39]. We therefore proceeded
to measure NFkB (p65) and IkB in the hippocampal
samples (Figure 3D).
Consistent with the notion of a pro-inflammatory condi-
tion in pre-plaque McGill-Thy1-APP mice, we observed
elevated levels of NFkB and IkB in the Tg Placebo animals
compared with Non Tg Placebo. Treatment with minocy-
cline in Tg animals resulted in lower levels of NFkB and
higher levels of IkB. On the other hand, minocycline-trea-
ted Non Tg mice showed increased NFkB and IkB levels.
None of these changes reached significance due to high
variability, but we found a very strong correlation between
BACE-1 levels and NFkB levels (Figure 3E, P < 0.001,
Spearman’s correlation analysis). These findings suggested
that BACE-1 levels might be under the direct or indirect
control of NFkB in vivo.
Discussion
Experimental design and novelty of the study
In the present studies, we aimed to elucidate the interac-
tion between activated glia and neurons in the earliest
stages of the AD pathology. Several reports in the field
have documented the effect of anti-inflammatory treat-
ments with NSAIDs in Tg models of AD-like pathology
[40-42]. However, these studies were designed to assess
the effect of treatment on plaque pathology, and the ani-
mals were sacrificed after plaque onset. Our approach dif-
fered from previous reports in that we wanted to clarify
the role of inflammation in the early, pre-plaque stages of
the pathology, which likely mimic the earliest, pre-clinical
stages in AD.
This is a matter of high clinical relevance, as the avail-
able data in humans suggest a differential role of inflam-
mation in early versus late stages of the disease. The
contribution of the inflammatory process in disease onset
has been highlighted by epidemiological, retrospective stu-
dies indicating a lower incidence of AD in populations
receiving long-term treatment with NSAIDs [43-46]. In
contrast, prospective trials applying NSAIDs to patients
clinically diagnosed with AD have failed to reverse or slow
down the disease, often worsening it [12-14]. Taken
together, the clinical evidence is consistent with the con-
cept that inflammation would contribute to and accelerate
the AD neuropathology in its early pre-clinical stages,
while it would be neutral or even beneficial in later,
clinical stages. It is important to note that this hypothesis
has been supported by the recent extended results from
an AD anti-inflammatory preventive trial (ADAPT). The
study had to be halted after only two years for safety con-
cerns [47]; at that point in time, no beneficial effects were
observed with the anti-inflammatory treatment [48]. How-
ever, the follow-up results indicated that the naproxen
treatment outcome critically depended on the stage of the
pathology at the moment of enrolment in the trial [49,50].
In this prospective study, in fact, an increased risk of AD
onset was detected in patients who displayed some cogni-
tive impairment (but no dementia) when they entered into
the study. Such a cohort would likely represent patients
closer to the disease onset. On the other hand, asympto-
matic individuals treated with NSAIDs had a reduced AD
incidence [49]. The concept of a differential role of inflam-
mation at early versus late stages of the disease has been
suggested for other neurodegenerative conditions, such as
amyotrophic lateral sclerosis [51], and it might very well
be related to the differential subsets of monocytic cells
involved [8]. Therefore, the temporal window in which
anti-inflammatory treatment can be beneficial and the
mechanism involved in such a beneficial effect need to be
further studied. We propose that pre-plaque Tg mice can
be a valuable model for this type of investigation.
Early microglial activation and its inhibition with
minocycline
In agreement with our previous observations [23], we
gathered biochemical (Figure 1A-C) and morphological
(Figure 1D-H) evidence indicating the presence of
microglial activation in the cerebral cortex and hippo-
campus at pre-plaque stages in the transgenic mouse
model McGill-Thy1-APP.
To investigate the pathological participation of such pro-
inflammatory process in the AD-like amyloid pathology,
we chose to administer the tetracyclic derivative minocy-
cline. In addition to its antimicrobial activities, this drug
easily crosses the blood-brain barrier and has been shown
to be beneficial in several CNS neuropathological condi-
tions and in neurodegeneration [52]. Minocycline appears
to exert its action through a plethora of mechanisms,
including inhibition of key inflammatory enzymes (such as
iNOS, matrix metalloprotease 9 and 5-lipoxygenase),
blocking caspase-dependent and independent apoptosis
and demonstrating anti-oxidant effects (for a review, see
[53]).
Previous reports have studied the effect of minocycline
on the full-blown amyloid pathology in APP Tg mice
[28,54-56]. Overall, the drug appeared to reduce neuroin-
flammation and the behavioral deficits observed in Tg
mice. However, in all the previous reports, the animals
were sacrificed after plaque onset and the effect on pre-
plaque pathology was not documented. Our study
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therefore represents the first report of the effect of mino-
cycline on early, pre-plaque stages of AD-like amyloid
pathology in Tg mice.
As expected, minocycline was indeed effective in redu-
cing inflammation, as COX-2, iNOS and IL-1b levels
were all found to be down-regulated in Tg animals trea-
ted with minocycline compared to placebo (Figure 1A-
C). After minocycline treatment, the microglial soma
size of hippocampal cells appeared to be significantly
reduced (Figure 1E and 1G), along with an increase in
the complexity of microglial arborization (as illustrated
in the representative micrograph in Figure 1E). Both
biochemical and morphological findings suggested
decreased pro-inflammatory activity. Given the well-
known complexity of the microglial phenotype [57], it is
possible that minocycline exerted its effect by switching
the microglial cells to a more neuroprotective, M2-like
phenotype. Further studies will be required to pinpoint
the features of microglia in response to minocycline
treatment, using alternative markers such as CD45 or
arginase-1 [58-60]. Interestingly, the anti-inflammatory
effect of minocycline was specific to the hippocampus
and the cortex, a region burdened with intracellular Ab-
oligomers [22]. In fact, microglial cells of the thalamus,
an area largely devoid of Ab material at this early age,
did not appear to be affected by the treatment (Figure
1F and 1H). This result indicates that minocycline speci-
fically interfered with a pathological inflammatory pro-
cess dependent on intracellular Ab accumulation.
Minocycline effects on the amyloid pathology
Having assessed the ability of minocycline to inhibit the
pre-plaque inflammatory process, we set ourselves to
study the consequences of such anti-inflammatory treat-
ment on the intracellular, pre-plaque phase of the amy-
loid pathology.
In our study, as opposed to previous reports of minocy-
cline in AD models, the treatment was started and fin-
ished when the animals were devoid of plaques.
Therefore, instead of plaque number, we focused our
investigation on the cerebral levels of APP, APP-related
products and soluble Ab following minocycline treat-
ment. Soluble levels of Ab are particularly important
indicators of the disease state, as they were shown to cor-
relate with the degree of dementia in AD patients [61].
On the other hand, it is well established that the amyloid
plaque burden does not correlate with the severity of the
disease [62,63].
In this regard we first noticed that, at this early time
point, inhibition of inflammation was associated with the
down-regulation of APP (Figure 2). While the cellular
mechanisms for such an effect remain to be determined,
there is evidence in the literature that inflammatory med-
iators can modulate APP synthesis. IL-1b, for instance,
was shown to induce APP synthesis in neurons [64,65].
The decrease in flAPP could therefore be a consequence
of reduced IL-1b levels.
Besides the down-regulation of flAPP, the most signifi-
cant effect we observed was the reduction of a 12-kDa
band recognized with the monoclonal antibody 6E10.
This band co-migrates with trimers of synthetic Ab and
is considered by some authors as oligomeric-Ab [66,67].
However, the epitope recognized by 6E10 is shared by
the C-terminus fragments of the amyloidogenic pathway
(b-CTF) and 6E10 is often used to detect b-CTF from
cell lysates and homogenates [68]. The fact that CTFs
migrate around 12 kDa, as do Ab trimers, complicated
the interpretation of the band. To clarify the nature of
this material we sought to specifically quantify CTF frag-
ments and human Ab in the same samples. This analysis
also allowed us to determine the relative abundance of
the two species in each brain.
Western blots using a specific antibody directed against
the C-terminus of full-length APP (pab27576) revealed a
reduction in the CTF content, which did not reach signif-
icance (Figure 2D and 2E). Even though the band recog-
nized by pab27576 perfectly overlapped with the band
seen with 6E10, the results did not fully match our analy-
sis with 6E10. It is possible that the discrepancy is due to
different specificity of the antibodies. Alternatively, some
CTF material from the non-amyloidogenic pathway
(aCTF which can be detected by pab27576 but not by
6E10) might have affected our quantification. We also
considered the possibility that the 12-kDa band was con-
stituted mostly of Ab species (trimers) and so performed
a highly sensitive ELISA assay for human Ab40 and
Ab42. No plaques were detected in the animals and,
from our previous study in this model, the Ab-ir species
are either monomeric or oligomeric at this stage [22].
Therefore, the Ab material measured via ELISA can be
considered as soluble in nature. Our analysis of such
soluble Ab material did reveal some degree of reduction
after treatment with minocycline, but the high variability
resulted in no statistical significance (Figure 2F). In sum-
mary, while the three analyses (western blot with 6E10,
pab27576 and ELISA) all showed a reduction of APP-
related products, the pattern observed with the 6E10
antibody was not fully reproduced by either that of CTF
or Ab alone. A likely explanation for this is that the 12-
kDa band recognized by 6E10 represents a mixture of b-
CTF and Ab-oligomers. In this view, it is possible that
minocycline treatment resulted in the reduction of both
species, which together reached significance. Neverthe-
less, further investigations are needed to clarify this point.
The simultaneous presence of Ab and APP-related
products in early, pre-plaque stages of the disease in Tg
models of AD is a highly controversial issue [69-73]. In
particular, their relative abundance and their specific
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contribution to the neuropathology have not been clari-
fied. We therefore took advantage of the data set pre-
sented here to explore the relative abundance of Ab and
CTF, and the effect of an anti-inflammatory treatment
on their ratio. We compared the absolute levels of CTF
(extrapolated from a recombinant CTF calibration
curve, using a semi-quantitative method) and Ab (mea-
sured via ELISA) from each sample. In Tg Placebo ani-
mals we observed (on average) 6.76 pg of Ab40 per each
ng of CTF, and 24 pg of Ab42 per each ng of CTF. In
terms of molar ratio, it appears that McGill-Thy1-APP
mice harbor about 84 molecules of CTF per each mole-
cule of Ab40 and about 24 molecules of CTF per each
molecule of Ab42. It is therefore very likely that, while
the species co-exist, b-CTF fragments represent the vast
majority of the material seen with 6E10, as suggested by
McAlpine et al. [74].
Beta-site APP cleaving enzyme 1-deregulation in young,
pre-plaque mice and its correction with minocycline
To further elucidate the effect of minocycline on APP
processing, we studied the levels and activity of BACE-1,
the most important b-site APP cleaving enzyme in the
brain [75].
Our analysis revealed that BACE-1 levels and activity
were up-regulated in the McGill-Thy1-APP Tg model,
in agreement with reports from sporadic AD [76-79]
and Tg models [24,80,81]. As described in young V717V
Tg mice [24], BACE-1 levels and activity were up-regu-
lated in McGill-Thy1-APP mice prior to plaque deposi-
tion. Therefore, deregulation of APP processing might
be an early event in the progression of the AD-like amy-
loid pathology. Minocycline treatment restored BACE-1
activity to control levels, and corrected BACE-1 protein
content in young, pre-plaque Tg mice (Figure 3). These
results would agree with the western blotting of 6E10
(Figure 2) in indicating reduced b-cleavage of APP upon
anti-inflammatory treatment.
Since the anti-inflammatory treatment with minocy-
cline was able to correct BACE-1 up-regulation in pre-
plaque Tg mice, it is very likely that the early deregula-
tion of BACE-1 prior to plaque deposition is related to
the pro-inflammatory process. This view is in line with
the body of evidence indicating that neuroinflammation
has a pivotal role in regulating BACE-1. In fact, several
studies have indicated that BACE-1 behaves as a stress-
response protein and its levels are increased by cyto-
kines [82], oxidative stress [83], astrocytic activation
[84], ischemia [85], hypoxia [86] and energy inhibition
[87]. On the other hand, we did not detect any effect of
minocycline treatment on the levels of Ab-degrading
enzymes such as insulin-degrading enzyme and neprily-
sin (data not shown).
Minocycline mechanism of action and effect on NFkB
In an attempt to clarify the mechanism of action of
minocycline, we measured the levels of NFkB, a key
transcription factor which is known to regulate the
expression of several inflammatory markers as well as
BACE-1 and APP [38,88,89]. Increased NFkB expression
is associated with neuroinflammatory conditions and it
has been reported in AD [90-93]. Elevated NFkB activity
was detected in Tg models of AD [94]. Interestingly,
since the promoter of the IkB gene contains several
NFkB binding sites [39], IkB expression is elevated in
response to NFkB activation following cerebral ischemia
[95] and lipopolysaccharide injections [96]. Increased
levels of IkB have also been reported in AD [93].
Consistent with the results from AD samples, we found
up-regulated levels of NFkB and its inhibitor, IkB, in Tg
animals compared to Non Tg Placebo animals. Given the
relatively high variability of the data, these changes did not
reach statistical significance; however, they support the
notion of a pro-inflammatory state in these brains.
Accordingly, NFkB levels were reduced following minocy-
cline treatment, while IkB was further up-regulated. A
reduction of NFkB with concomitant up-regulation of IkB
has been reported for other anti-inflammatory agents such
as ibuprofen [97] and for glucocorticoids [98]. The
increase in IkB levels is thought to further potentiate the
anti-inflammatory effect, as any NFkB molecule synthe-
sized by the cell will associate with the inhibitor and be
prevented from entering the nucleus. These results, even
though they did not reach significance, suggested that
minocycline treatment in Tg animals resulted in an overall
decreased activity of NFkB.
Furthermore, the levels of NFkB strongly correlated with
BACE-1 levels in each sample. These results are consistent
with the concept that BACE-1 levels and activity are
tightly linked to NFkB levels in vivo. Even though this type
of correlative analysis cannot prove causality, several indi-
cations exist that NFkB regulates BACE in vivo. Paris et al.
have recently shown that the NFkB inhibitor celastrol is
capable of inhibiting BACE and reducing amyloidogenic
pathway in a mouse Tg model of AD [99]. Similarly, a
reduction in BACE-1 and Ab levels was found in Tg mice
acutely treated with the NSAID ibuprofen [100]. This drug
is endowed with multiple COX- independent mechanisms
of action, including inhibition of NFkB signaling [101],
peroxisome proliferator activated receptor-gamma activa-
tion [82] and gamma-secretase modulation [41]. It is very
likely that, like ibuprofen, minocycline exerts its beneficial
effects via multiple mechanisms of action.
Based on our results, one could speculate that the
inflammation-induced hyperactivity of NFkB is responsi-
ble for the increased transcription of BACE-1 in Tg ani-
mals. This might represent a possible mechanism for
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the glia-to-neuron or neuron-to-glia communication in
early AD, whereby the activation state of microglia can
instruct the processing of APP in neurons. Alternatively,
the reduction of inflammatory markers and the reduc-
tion in BACE-1 (levels and activity) following minocy-
cline treatment might be parallel, unrelated events
sharing the same up-stream events (that is, inhibition of
NFkB in glia and neurons).
Minocycline adverse effects
It is important to note that the intraperitoneal applica-
tion of 50 mg/Kg/day of minocycline resulted in some
toxicity: one out of eight mice (12.5%) in the Non Tg
group and two out of seven mice (28%) in the Tg group
died, while the remaining mice showed signs of liver
toxicity and peritoneal irritation. These adverse effects
precluded the completion of behavioral testing for learn-
ing and memory, such as the Morris water maze task.
Liver toxicity [102] and peritoneal inflammation [103]
are known side effects of intraperitoneal administration
of minocycline which are seldom referred to in numer-
ous experimental published studies. It has been estab-
lished that the peripheral inflammatory process can
have an impact on the microglial status in the CNS
[104,105]. Indeed, the occurrence of some glial activa-
tion following minocycline treatment is supported by
the rise in NFkB levels and BACE-1 activity in the Non
Tg Mino group. However, these alterations were not
accompanied by classical pro-inflammatory activity, as
COX-2, iNOS and IL-1b were not found to be signifi-
cantly different from Non Tg Placebo. As the intraperi-
toneal application of the drug was not inert, we cannot
rule out the possibility that peripheral toxicity could
have had some role in the CNS effects observed in the
Tg-treated mice.
While the dose and administration route of the drug
need to be optimized to avoid adverse peripheral effects,
our overall results indicate that the inhibition of neu-
roinflammation with minocycline can be beneficial in
early pre-plaque stages of AD-like amyloid pathology.
Conclusions
This report demonstrates that the early, pre-plaque
inflammatory process occurring at the initial stages of
AD-like amyloid pathology can be modulated pharmaco-
logically by the application of minocycline. The down-
regulation of inflammatory markers was accompanied by
a reduction of APP levels and correction of BACE-1
hyperactivity. Our results indicate that inflammation has
a pivotal role in the early stages of the disease, including
the modulation of APP metabolism. Interfering with
inflammation could be a useful therapeutic approach in
early, pre-plaque stages of AD-like amyloid pathology.
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